Amgen Epogen boosts hematocrit levels in anemic ESRD patients, improves quality of life, study says.
Executive Summary
AMGEN EPOGEN RAISES HEMATOCRIT LEVELS UP TO 30% FROM 26% AT BASELINE at first follow-up reported in kidney dialysis patients who were treated with epoietin alfa therapy for anemia. The patients were part of the 2,100-person open-label, multi-center National Cooperative Recombinant Human Erythropoietin Study published in the May issue of the Journal of the American Society of Nephrology. At the time of the Amgen-sponsored study, which began in 1990, recommended hematocrit ranges were 30%-33%; the recommended range since has been broadened to 30%-36%, Amgen noted.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth